99295-33-7
基本信息
SKF 83566 HYDROBROMIDE
(+/-)-SKF-83566 HYDROCHLORIDE SELECTIVE DOPAMINE D1
8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol
1H-3-Benzazepin-7-ol, 8-broMo-2,3,4,5-tetrahydro-3-Methyl-5-phenyl-
8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE
(±)-SCH-24543, (±)-7-Bromo-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
物理化学性质
| 储存条件 | Desiccate at RT |
| 溶解度 | 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: ≥14 mg/mL |
| 形态 | solid |
| 颜色 | light tan |
安全数据
| WGK Germany | 3 |
图谱信息
8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE(99295-33-7)核磁图(1HNMR)8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2023/03/20 | HY-103430 | 8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE SKF-83566 hydrobromide | 99295-33-7 | 5mg | 950元 |
| 2023/03/20 | HY-103430 | 8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE SKF-83566 hydrobromide | 99295-33-7 | 10mg | 1500元 |
| 2023/03/20 | HY-103430 | 8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE SKF-83566 hydrobromide | 99295-33-7 | 25mg | 2700元 |
常见问题列表
|
D 1 Receptor
|
D 5 Receptor
|
5-HT 2 Receptor 11 nM (Ki) |
SKF-83566 (0.1 μM-10 μM) causes a concentration-dependent increase in peak evoked extracellular DA concentration ([DA] o ) evoked by single-pulse stimulation, with a maximum 65% increase in peak evoked [DA] o with 5 μM. The EC 50 value of this effect of SKF-83566 is 1.3 μM.SKF-83566 inhibited [ 3 H]DA uptake with an IC 50 of 5.73 μM. Moreover, SKF-83566 more potently inhibits the binding of [ 3 H]CFT, a cocaine analog, with an IC 50 of 0.51 μM in [ 3 H]DA uptake and [ 3 H]CFT binding studies.Similarly, in LLc-PK-rDAT cell, SKF-83566 also inhibits [ 3 H]CFT binding with an IC 50 of 0.77 μM in LLc-PK-rDAT cell membrane preparations.
SKF 83566 hydrobromide (oral administration; 20 µg/mL; 7 days) alone has no effects on altering LTP (115%). However, combinnation of SKF 83566 and nicotine significantly blocks the enhancement of long-term synaptic potentiation (LTP) induced by pretreatment with nicotine (SKF 83566+nicotine+cocaine, 120%; nicotine+cocaine, 143%).
| Animal Model: | Male C57BL6/J mice (6- to 9-wk-old) |
| Dosage: | 20 µg/mL (Together with nicotine for 7 d, followed by the injection of cocaine) |
| Administration: | Oral administration; 7 days |
| Result: | Blocked nicotine and cocaine-induced facilitation of LTP. |